Back To Search Instructions
Protocols
12 protocols meet the specified criteria
Disease Site: Pancreas
Protocol No.TitleStatus
0200000785Core: A Tissue Resource (SPORE in GI Cancer)Open
1702242206A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects with Advanced MalignanciesOpen
1703306023A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing RegimenOpen
1704345989Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma with Molecular Correlates Open
1704390293A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsOpen
1707664489A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination with Abraxane® in Subjects with Metastatic Pancreatic CancerOpen
1711993144A Prospective Quality of Life Study in Metastatic Pancreatic CancerOpen
1712087417FIGHT: A Phase 1/3 Study of FPA144 versus Placebo in Combination with Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal CancerOpen
1803362975I5B-MC-JGDP(c) A Phase 1b (Open-Label) / Phase 2 (Randomized,Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer Not Open
PHXB-17-0013-71-16Dosimetric comparison for IMRT, VMAT, SBRT/SRS, & Brachytherapy for extracranial sitesOpen
PHXE-17-0216-10-15EAY131: Molecular Analysis for Therapy Choice (MATCH) Open
PHXE-17-0349-10-15DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsOpen